Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial Of BAY 43-9006, A Novel Raf Kinase Inhibitor Plus Paclitaxel/Carboplatin In Women With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer
Brief Summary: Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving sorafenib together with chemotherapy may kill more tumor cells. This randomized phase II trial is studying how well giving sorafenib together with paclitaxel and carboplatin works in treating patients with recurrent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. (Sorafenib only group closed as of 10/10/2008).


Options:
A: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Arm B, Arm C | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm B, Arm C
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Placebo olaparib, Drug: Durvalumab placebo, Drug: Carboplatin+Paclitaxel | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Durvalumab, Drug: Placebo olaparib, Drug: Carboplatin+Paclitaxel | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Durvalumab, Drug: Olaparib, Drug: Carboplatin+Paclitaxel | Arm Label: tBRCAm cohort; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Durvalumab, Drug: Olaparib, Drug: Carboplatin+Paclitaxel | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, tBRCAm cohort | Intervention Type: DRUG; Name: Durvalumab; Assigned to Arm(s): Arm 2, Arm 3, tBRCAm cohort | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm 3, tBRCAm cohort | Intervention Type: DRUG; Name: Placebo olaparib; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Durvalumab placebo; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Carboplatin+Paclitaxel; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, tBRCAm cohort
C: Arm Label: Arm I (closed to accrual 10/10/2008); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib Tosylate | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Sorafenib Tosylate | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm I (closed to accrual 10/10/2008), Arm II
D: Arm Label: chemotherapy, avelumab and talazoparib; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy + avelumab followed by avelumab + talazoparib | Arm Label: chemotherapy, and talazoparib; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy followed by talazoparib maintenance | Arm Label: chemotherapy and bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy + bevacizumab followed by bevacizumab | Intervention Type: DRUG; Name: Chemotherapy + avelumab followed by avelumab + talazoparib; Assigned to Arm(s): chemotherapy, avelumab and talazoparib | Intervention Type: DRUG; Name: Chemotherapy followed by talazoparib maintenance; Assigned to Arm(s): chemotherapy, and talazoparib | Intervention Type: DRUG; Name: Chemotherapy + bevacizumab followed by bevacizumab; Assigned to Arm(s): chemotherapy and bevacizumab

Answer: C